MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
Panelists discuss how long-term follow-up data from MajesTEC-1 demonstrates teclistamab’s sustained efficacy and safety profile while identifying optimal candidates based on factors like prior therapy exposure, disease characteristics, and fitness level.
EP: 1.Brief Overview of Therapeutic Landscape for R/R MM
EP: 2.Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma
EP: 3.MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
EP: 4.Elranatamab Dosing Strategies: Implications for Community Practice
EP: 5.Navigating Post–CAR T Progression: Therapy Selection and Targeting
Video content above is prompted by the following:
- Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab
- Is there a patient population who would benefit most from this treatment regimen?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
